CAC
DNA.WS

Cowen and Company’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Cowen and Company’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,663,614
Closed -$75.1K – 738
2024
Q2 		$75.1K Buy
2,663,614
+1,281,281
+93% +$68.8K ﹤0.01% 285
2024
Q1 		$124K Buy
1,382,333
+454,764
+49% +$43.4K ﹤0.01% 272
2023
Q4 		$97.7K Buy
927,569
+484,367
+109% +$71.3K 0.01% 244
2023
Q3 		$99.7K Buy
443,202
+185,485
+72% +$49.8K 0.01% 253
2023
Q2 		$67.6K Buy
257,717
+67,099
+35% +$13.1K 0.01% 258
2023
Q1 		$34.3K Sell
190,618
-60,408
-24% -$13.8K ﹤0.01% 253
2022
Q4 		$50.2K Buy
+251,026
New +$108K 0.01% 259

Other funds holding DNA.WS

AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
SBLIC
Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Cowen and Company's DNA.WS Position: Q3 2024 in Review

Cowen and Company sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q3 2024, closing a stake of 2,663,614 shares — an estimated $75.1K sold.

Cowen and Company first reported a position in DNA.WS in Q4 2022 and held it in 7 quarters. The position peaked at $124K in Q1 2024. 5 funds tracked by Wall St. Rank hold DNA.WS as of Q3 2024.

  • Cowen and Company reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q3 2024 after selling out during the quarter.
  • Cowen and Company sold 2,663,614 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q3 2024, an estimated $75.1K.
  • Cowen and Company first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q4 2022 and held it in 7 quarters.
  • Cowen and Company's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $124K in Q1 2024.
  • 5 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q3 2024.

Based on Cowen and Company's 13F filing for Q3 2024, filed 12 Nov 2024.